Isomorphic Labs Secures $600M to Advance AI-Driven Drug Discovery

The funding, led by Thrive Capital, will accelerate the development of the company’s next-gen AI drug design engine and clinical programs.

Isomorphic Labs, a spinout of Google DeepMind, raised $600 million in its first external funding round, led by Thrive Capital with participation from Google Ventures and Alphabet.
The company plans to use the funding to enhance its AI drug design engine, expand its team, and advance its programs into clinical development by the end of 2025.
Isomorphic Labs collaborates with pharmaceutical giants Eli Lilly and Novartis, recently expanding its partnership with Novartis to include three additional drug discovery programs.
The company’s AlphaFold technology, developed with Google DeepMind, has revolutionized protein structure prediction and is being applied to accelerate drug discovery.
With an ambitious mission to ‘solve all diseases,’ Isomorphic Labs is positioning itself as a leader in the rapidly growing AI-driven biotech sector.